The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer

Masayuki Kawasaki, Yoichi Nakanishi, Kazuyoshi Kuwano, Jun Yatsunami, Koichi Takayama, Nobuyuki Hara

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

There are few reports on the p53 status of small cell lung cancer (SCLC) and advanced non-SCLC (NSCLC) because surgically resected specimens are generally not available. Therefore, we evaluated p53 immunostaining in 175 transbronchial biopsy (TBB) specimens obtained from patients with all stages of lung cancer and retrospectively evaluated the relationship between p53 status and clinical parameters. All of the specimens were obtained prior to therapy. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using an anti-p53 antibody (DO-1). p53 protein was detected in 55% (61 of 111) of NSCLCs and 58% (37 of 64) of SCLCs. The rate of positivity increased significantly with increasing stage (stages I and II, 45%; stage III, 54%; stage IV, 66%), but not with other clinical parameters. Ninety-five patients were evaluated for their response to chemotherapy. Positive staining for p53 correlated significantly with unresponsiveness to chemotherapy in NSCLC (response rate of 13 versus 60%; P = 0.006), but not in SCLC (80 versus 57%; P = 0.22). p53 positivity was a statistically significant negative prognostic factor for stage III and stage IV NSCLC (P = 0.02), but not for stage I and stage II NSCLC (P = 0.79). There was no survival difference relative to p53 status in SCLC (P = 0.35). These results indicate that p53 overexpression in TBB specimens predicts poor prognosis and chemoresistance in advanced stage NSCLC.

Original languageEnglish
Pages (from-to)1195-1200
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number7
Publication statusPublished - Jul 1 1997

Fingerprint

Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Biopsy
Drug Therapy
Paraffin
Formaldehyde
Anti-Idiotypic Antibodies
Staining and Labeling
Survival
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer : p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. / Kawasaki, Masayuki; Nakanishi, Yoichi; Kuwano, Kazuyoshi; Yatsunami, Jun; Takayama, Koichi; Hara, Nobuyuki.

In: Clinical Cancer Research, Vol. 3, No. 7, 01.07.1997, p. 1195-1200.

Research output: Contribution to journalArticle

Kawasaki, Masayuki ; Nakanishi, Yoichi ; Kuwano, Kazuyoshi ; Yatsunami, Jun ; Takayama, Koichi ; Hara, Nobuyuki. / The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer : p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 7. pp. 1195-1200.
@article{61a8725e304b4d1e980fa13ae26d693f,
title = "The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer",
abstract = "There are few reports on the p53 status of small cell lung cancer (SCLC) and advanced non-SCLC (NSCLC) because surgically resected specimens are generally not available. Therefore, we evaluated p53 immunostaining in 175 transbronchial biopsy (TBB) specimens obtained from patients with all stages of lung cancer and retrospectively evaluated the relationship between p53 status and clinical parameters. All of the specimens were obtained prior to therapy. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using an anti-p53 antibody (DO-1). p53 protein was detected in 55{\%} (61 of 111) of NSCLCs and 58{\%} (37 of 64) of SCLCs. The rate of positivity increased significantly with increasing stage (stages I and II, 45{\%}; stage III, 54{\%}; stage IV, 66{\%}), but not with other clinical parameters. Ninety-five patients were evaluated for their response to chemotherapy. Positive staining for p53 correlated significantly with unresponsiveness to chemotherapy in NSCLC (response rate of 13 versus 60{\%}; P = 0.006), but not in SCLC (80 versus 57{\%}; P = 0.22). p53 positivity was a statistically significant negative prognostic factor for stage III and stage IV NSCLC (P = 0.02), but not for stage I and stage II NSCLC (P = 0.79). There was no survival difference relative to p53 status in SCLC (P = 0.35). These results indicate that p53 overexpression in TBB specimens predicts poor prognosis and chemoresistance in advanced stage NSCLC.",
author = "Masayuki Kawasaki and Yoichi Nakanishi and Kazuyoshi Kuwano and Jun Yatsunami and Koichi Takayama and Nobuyuki Hara",
year = "1997",
month = "7",
day = "1",
language = "English",
volume = "3",
pages = "1195--1200",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer

T2 - p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer

AU - Kawasaki, Masayuki

AU - Nakanishi, Yoichi

AU - Kuwano, Kazuyoshi

AU - Yatsunami, Jun

AU - Takayama, Koichi

AU - Hara, Nobuyuki

PY - 1997/7/1

Y1 - 1997/7/1

N2 - There are few reports on the p53 status of small cell lung cancer (SCLC) and advanced non-SCLC (NSCLC) because surgically resected specimens are generally not available. Therefore, we evaluated p53 immunostaining in 175 transbronchial biopsy (TBB) specimens obtained from patients with all stages of lung cancer and retrospectively evaluated the relationship between p53 status and clinical parameters. All of the specimens were obtained prior to therapy. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using an anti-p53 antibody (DO-1). p53 protein was detected in 55% (61 of 111) of NSCLCs and 58% (37 of 64) of SCLCs. The rate of positivity increased significantly with increasing stage (stages I and II, 45%; stage III, 54%; stage IV, 66%), but not with other clinical parameters. Ninety-five patients were evaluated for their response to chemotherapy. Positive staining for p53 correlated significantly with unresponsiveness to chemotherapy in NSCLC (response rate of 13 versus 60%; P = 0.006), but not in SCLC (80 versus 57%; P = 0.22). p53 positivity was a statistically significant negative prognostic factor for stage III and stage IV NSCLC (P = 0.02), but not for stage I and stage II NSCLC (P = 0.79). There was no survival difference relative to p53 status in SCLC (P = 0.35). These results indicate that p53 overexpression in TBB specimens predicts poor prognosis and chemoresistance in advanced stage NSCLC.

AB - There are few reports on the p53 status of small cell lung cancer (SCLC) and advanced non-SCLC (NSCLC) because surgically resected specimens are generally not available. Therefore, we evaluated p53 immunostaining in 175 transbronchial biopsy (TBB) specimens obtained from patients with all stages of lung cancer and retrospectively evaluated the relationship between p53 status and clinical parameters. All of the specimens were obtained prior to therapy. Formalin-fixed, paraffin-embedded TBB specimens were immunostained using an anti-p53 antibody (DO-1). p53 protein was detected in 55% (61 of 111) of NSCLCs and 58% (37 of 64) of SCLCs. The rate of positivity increased significantly with increasing stage (stages I and II, 45%; stage III, 54%; stage IV, 66%), but not with other clinical parameters. Ninety-five patients were evaluated for their response to chemotherapy. Positive staining for p53 correlated significantly with unresponsiveness to chemotherapy in NSCLC (response rate of 13 versus 60%; P = 0.006), but not in SCLC (80 versus 57%; P = 0.22). p53 positivity was a statistically significant negative prognostic factor for stage III and stage IV NSCLC (P = 0.02), but not for stage I and stage II NSCLC (P = 0.79). There was no survival difference relative to p53 status in SCLC (P = 0.35). These results indicate that p53 overexpression in TBB specimens predicts poor prognosis and chemoresistance in advanced stage NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0030760737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030760737&partnerID=8YFLogxK

M3 - Article

C2 - 9815799

AN - SCOPUS:0030760737

VL - 3

SP - 1195

EP - 1200

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -